Skip to main content

letter

. 1985 Aug;20(2):178–180. doi: 10.1111/j.1365-2125.1985.tb05056.x

Clinically significant sucralfate-warfarin interaction is not likely.

P J Neuvonen, A Jaakkola, J Tötterman, O Penttilä

PMCID: PMC1400679 PMID: 3840028

178

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease. Drugs. 1984 Mar;27(3):194–209. doi: 10.2165/00003495-198427030-00002. [DOI] [PubMed] [Google Scholar]
OWREN P. A., AAS K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3(3):201–208. doi: 10.3109/00365515109060600. [DOI] [PubMed] [Google Scholar]
Robinson D. S., Benjamin D. M., McCormack J. J. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971 May-Jun;12(3):491–495. doi: 10.1002/cpt1971123491. [DOI] [PubMed] [Google Scholar]
Serlin M. J., Breckenridge A. M. Drug interactions with warfarin. Drugs. 1983 Jun;25(6):610–620. doi: 10.2165/00003495-198325060-00004. [DOI] [PubMed] [Google Scholar]
Tasker R. A., Nakatsu K. Rapid, reliable and sensitive assay for warfarin using normal-phase high-performance liquid chromatography. J Chromatogr. 1982 Mar 12;228:346–349. doi: 10.1016/s0378-4347(00)80452-1. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES